{
  "paper_metadata": {
    "pmid": "24877995",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted information on KCNH2 variants and their functional impact from the study on ranolazine inhibition of hERG potassium channels."
  },
  "variants": [
    {
      "gene_symbol": "KCNH2",
      "cdna_notation": null,
      "protein_notation": "p.Ser620Thr",
      "genomic_position": null,
      "clinical_significance": "likely pathogenic",
      "patients": {
        "count": null,
        "demographics": "",
        "phenotype": "Inactivation deficient"
      },
      "penetrance_data": {
        "total_carriers_observed": null,
        "affected_count": null,
        "unaffected_count": null,
        "uncertain_count": null,
        "penetrance_percentage": null,
        "age_dependent_penetrance": []
      },
      "individual_records": [],
      "functional_data": {
        "summary": "S620T mutation results in inactivation deficiency and significantly reduces ranolazine potency (~73-fold increase in IC50).",
        "assays": [
          "Electrophysiological recordings",
          "Concentration-response analysis"
        ]
      },
      "segregation_data": null,
      "population_frequency": null,
      "evidence_level": "high",
      "source_location": "Results, paragraph 4",
      "additional_notes": "The S620T mutation is used to determine true drug affinity for the open/activated channel.",
      "key_quotes": [
        "The IC50 values for ranolazine inhibition of the S620T inactivation deficient and N588K attenuated inactivation mutants were respectively ~ 73-fold and ~ 15-fold that for WT IhERG."
      ]
    },
    {
      "gene_symbol": "KCNH2",
      "cdna_notation": null,
      "protein_notation": "p.Asn588Lys",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": null,
        "demographics": "",
        "phenotype": "Attenuated inactivation, associated with SQT1"
      },
      "penetrance_data": {
        "total_carriers_observed": null,
        "affected_count": null,
        "unaffected_count": null,
        "uncertain_count": null,
        "penetrance_percentage": null,
        "age_dependent_penetrance": []
      },
      "individual_records": [],
      "functional_data": {
        "summary": "N588K mutation results in attenuated inactivation and reduces ranolazine potency (~15-fold increase in IC50).",
        "assays": [
          "Electrophysiological recordings",
          "Concentration-response analysis"
        ]
      },
      "segregation_data": null,
      "population_frequency": null,
      "evidence_level": "high",
      "source_location": "Results, paragraph 4",
      "additional_notes": "The N588K mutation is responsible for the SQT1 variant of short QT syndrome.",
      "key_quotes": [
        "The N588K mutation is responsible for the SQT1 variant of short QT syndrome and our data suggest that ranolazine is unlikely to be effective against IKr/hERG in SQT1 patients."
      ]
    },
    {
      "gene_symbol": "KCNH2",
      "cdna_notation": null,
      "protein_notation": "p.Tyr652Ala",
      "genomic_position": null,
      "clinical_significance": "likely pathogenic",
      "patients": {
        "count": null,
        "demographics": "",
        "phenotype": "Reduced ranolazine block"
      },
      "penetrance_data": {
        "total_carriers_observed": null,
        "affected_count": null,
        "unaffected_count": null,
        "uncertain_count": null,
        "penetrance_percentage": null,
        "age_dependent_penetrance": []
      },
      "individual_records": [],
      "functional_data": {
        "summary": "Y652A mutation significantly reduces ranolazine block (~22-fold increase in IC50).",
        "assays": [
          "Electrophysiological recordings",
          "Concentration-response analysis"
        ]
      },
      "segregation_data": null,
      "population_frequency": null,
      "evidence_level": "high",
      "source_location": "Results, paragraph 4",
      "additional_notes": "Y652 is a key binding determinant for ranolazine.",
      "key_quotes": [
        "The Y652A and F656A S6 mutations had IC50s ~ 22-fold and 53-fold WT controls."
      ]
    },
    {
      "gene_symbol": "KCNH2",
      "cdna_notation": null,
      "protein_notation": "p.Phe656Ala",
      "genomic_position": null,
      "clinical_significance": "likely pathogenic",
      "patients": {
        "count": null,
        "demographics": "",
        "phenotype": "Greatly attenuated ranolazine block"
      },
      "penetrance_data": {
        "total_carriers_observed": null,
        "affected_count": null,
        "unaffected_count": null,
        "uncertain_count": null,
        "penetrance_percentage": null,
        "age_dependent_penetrance": []
      },
      "individual_records": [],
      "functional_data": {
        "summary": "F656A mutation greatly attenuates ranolazine block (~53-fold increase in IC50).",
        "assays": [
          "Electrophysiological recordings",
          "Concentration-response analysis"
        ]
      },
      "segregation_data": null,
      "population_frequency": null,
      "evidence_level": "high",
      "source_location": "Results, paragraph 4",
      "additional_notes": "F656 is a key binding determinant for ranolazine.",
      "key_quotes": [
        "The Y652A and F656A S6 mutations had IC50s ~ 22-fold and 53-fold WT controls."
      ]
    }
  ],
  "tables_processed": [],
  "extraction_metadata": {
    "total_variants_found": 4,
    "extraction_confidence": "high",
    "challenges": [
      "No individual-level penetrance data was provided in the paper."
    ],
    "notes": "The paper focused on functional assays and drug interactions with KCNH2 variants, without providing individual-level clinical data."
  }
}